Skip to content

Drug-Eluting Central Venous Catheters Versus Conventional Central Venous Catheters for Intravenous Access in Patients Undergoing Abdominal Surgery: A Pragmatic, Multicenter, Randomized Controlled Trial (LIGHT-005)

Drug-Eluting Central Venous Catheters Versus Conventional Central Venous Catheters for Intravenous Access in Patients Undergoing Abdominal Surgery: A Pragmatic, Multicenter, Randomized Controlled Trial (LIGHT-005)

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104112
Enrollment
Unknown
Registered
2025-06-11
Start date
2025-06-16
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing abdominal surgery who require a Central Venous Catheter (CVC) for intravenous access.

Interventions

Control group:Non-drug-coated Central Venous Catheter (CVC)
Test group:Drug-coated Central Venous Catheter (CVC)

Sponsors

The First Affiliated Hospital of Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The patient voluntarily joins this study and signs the informed consent form. 2. Age is 18 years or older and 80 years or younger. 3. Use CVC for abdominal surgery patients receiving intravenous infusion. 4. The size of the blood vessels is sufficient to support a 7-Fr or larger CVC catheter. 5. Patients expected to have catheter retention for more than 5 days.

Exclusion criteria

Exclusion criteria: 1. It is known that there is a history of allergy for those allergic to research drugs or excipients. 2. There is currently a catheter-related bloodstream infection. 3. Thrombosis occurs in the vein where the CVC is planned to be inserted. 4. Previously participated in this study. 5. Researchers believe that other factors unsuitable for participation in this study include but are not limited to: severe bleeding (coagulation) disorders; persistent shock; infection at the puncture site; obstruction or damage of access routes such as the superior (inferior) vena cava, subclavian vein, internal jugular vein, and femoral vein; pregnant women.

Design outcomes

Primary

MeasureTime frame
Functional effectiveness of CVC;

Secondary

MeasureTime frame
Complications of all-cause CVC;Safety outcomes;

Countries

China

Contacts

Public ContactZhiyu Chen

The First Affiliated Hospital of Army Medical University

chenzhiyu_umn@163.com+86 23 65460505

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026